Optimization of carboxylate-terminated poly(amidoamine) dendrimer-mediated cisplatin formulation |
| |
Authors: | Hitesh Kulhari Deep Pooja Mayank K. Singh |
| |
Affiliation: | 1. IICT-RMIT Research Centre,;2. Medicinal Chemistry &3. Pharmacology Division, Indian Institute of Chemical Technology, Hyderabad, India, and;4. Medicinal Chemistry & |
| |
Abstract: | Cisplatin is mainly used in the treatment of ovarian, head and neck and testicular cancer. Poor solubility and non-specific interactions causes hurdles in the development of successful cisplatin formulation. There were few reports on poly(amidoamine) (PAMAM) dendrimer–cisplatin complexes for anticancer treatment. But the earlier research was mainly focused on therapeutic effect of PAMAM dendrimer–cisplatin complex, with less attention paid on the formulation development of these complexes. Objective of the present study is to optimize and validate the carboxylate-terminated, EDA core PAMAM dendrimer-based cisplatin formulation with respect to various variables such as dendrimer core, generation, drug entrapment, purification, yield, reproducibility, stability, storage and in-vitro release. Dendrimer–cisplatin complex was prepared by an efficient method which significantly increases the % platinum (Pt) content along with the product yield. Dendrimers showed reproducible (~27%) platinum loading by weight. Variation in core and generations does not produce significant change in the % Pt content. Percentage Pt content of dendrimeric formulation increases with increase in drug/dendrimer mole ratio. Formulation with low drug/dendrimer mole ratio showed delayed release compared to the higher drug/dendrimer mole ratio; these dendrimer formulations are stable in room temperature. In vitro release profiles of the stored dendrimer–cisplatin samples showed comparatively slow release of cisplatin, which may be due to formation of strong bond between cisplatin and dendrimer. This study will contribute to create a fine print for the formulation development of PAMAM dendrimer–cisplatin complexes. |
| |
Keywords: | Cisplatin encapsulation formulation optimization poly(amidoamine) dendrimer |
|
|